Last reviewed · How we verify
Dabigatran + clopidogrel
Dabigatran + clopidogrel is a Anticoagulant + antiplatelet agent combination Small molecule drug developed by Zuyderland Medisch Centrum. It is currently FDA-approved for Acute coronary syndrome or post-percutaneous coronary intervention with atrial fibrillation.
This combination uses dabigatran (a direct thrombin inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects.
This combination uses dabigatran (a direct thrombin inhibitor) and clopidogrel (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects. Used for Acute coronary syndrome or post-percutaneous coronary intervention with atrial fibrillation.
At a glance
| Generic name | Dabigatran + clopidogrel |
|---|---|
| Sponsor | Zuyderland Medisch Centrum |
| Drug class | Anticoagulant + antiplatelet agent combination |
| Target | Thrombin (Factor IIa) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dabigatran directly inhibits thrombin (Factor IIa), preventing the conversion of fibrinogen to fibrin and blocking the coagulation cascade. Clopidogrel irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. Together, this combination provides both anticoagulation and antiplatelet activity for thrombotic prevention.
Approved indications
- Acute coronary syndrome or post-percutaneous coronary intervention with atrial fibrillation
Common side effects
- Bleeding
- Dyspepsia
- Gastrointestinal hemorrhage
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dabigatran + clopidogrel CI brief — competitive landscape report
- Dabigatran + clopidogrel updates RSS · CI watch RSS
- Zuyderland Medisch Centrum portfolio CI
Frequently asked questions about Dabigatran + clopidogrel
What is Dabigatran + clopidogrel?
How does Dabigatran + clopidogrel work?
What is Dabigatran + clopidogrel used for?
Who makes Dabigatran + clopidogrel?
What drug class is Dabigatran + clopidogrel in?
What development phase is Dabigatran + clopidogrel in?
What are the side effects of Dabigatran + clopidogrel?
What does Dabigatran + clopidogrel target?
Related
- Drug class: All Anticoagulant + antiplatelet agent combination drugs
- Target: All drugs targeting Thrombin (Factor IIa) and P2Y12 receptor
- Manufacturer: Zuyderland Medisch Centrum — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome or post-percutaneous coronary intervention with atrial fibrillation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing